Objective Capital Partners, a leading middle market investment banking firm focused on mergers & acquisitions (M&A), valuation advisory, and corporate development services, is pleased to announce that it served as the exclusive financial advisor to MabVax Therapeutics Holdings, Inc., a clinical-stage immuno-oncology drug development company, on its sale of multiple assets to BioNTech SE, a clinical-stage biotechnology company focused on patient-specific immunotherapies for the treatment of cancer.
In addition to acquiring the lead candidate MVT-5873, BioNTech has purchased MabVax Therapeutics’ infrastructure and laboratory equipment with the intention of establishing a research facility in San Diego, CA.
“Objective Capital is proud to have contributed to the combined efforts of medical innovators like MabVax Therapeutics and BioNTech to create unprecedented drug programs, pre-clinical or clinical stage, to diagnose and treat cancers, pancreatitis, and other diseases,” said David H. Crean Ph.D., Managing Director at Objective Capital’s Life Sciences and Healthcare Practice. “It was a pleasure to work with David Hansen and we are privileged to have had this opportunity to realize the maximum value of MabVax’s assets while simultaneously facilitating the emergence of a powerful healthcare group and new, promising therapies for cancer patients.”
“The Objective Capital team did a remarkable job providing us with guidance navigating multiple transactions and positioning MabVax to maximize value for its shareholders.” said David Hansen, CEO of MabVax.
MabVax Therapeutics was a clinical-stage biotechnology company with a fully human antibody discovery platform focused on the rapid translation into clinical development of products to address unmet medical needs in the treatment of cancer. The Company was founded in 2006, and is based in San Diego, CA. MabVax worked with collaborators such as Memorial Sloan Kettering Cancer Center, Rockefeller University, Sarah Cannon Research Institute, Honor Health, and Imaging Endpoints to treat patients in clinical studies with their portfolio of clinical drug candidates.
About Objective Capital Partners
Objective Capital Partners, LLC is a leading investment banking and valuation advisory firm serving privately held and public companies in an effort to maximize our clients’ M&A, valuation advisory, capital raising, and corporate development results. Founded in 2006, Objective’s seasoned professionals have collectively executed over 500 M&A and advisory engagements within its five industries of focus which are Life Sciences, Healthcare, Technology, Consumer, and Business Services. Objective Capital is fiercely committed to helping entrepreneurs and business owners maximize the value of their business using our world-class, industry-specific advisory services. For more information on Objective Capital Partners, please visit: https://objectivecp.com.
About MabVax Therapeutics Holdings, Inc.
MabVax Therapeutics Holdings, Inc. was a clinical-stage biotechnology company with a fully human antibody discovery platform focused on the rapid translation into clinical development of products to address unmet medical needs in the treatment of cancer and pancreatitis. MabVax discovered a pipeline of human monoclonal antibody product candidates based on the protective immune responses generated by patients who have been vaccinated against targeted cancers. The therapeutic vaccine product candidates were discovered at Memorial Sloan Kettering Cancer Center (“MSK”) and are exclusively licensed to MabVax as well as exclusive rights to blood samples from patients who were vaccinated with the same licensed vaccines.
BioNTech SE is Europe’s largest privately-held biopharmaceutical company pioneering the development of precision immunotherapies for individualized treatment of cancer and prevention of infectious diseases. The company combines all building blocks for more precise and individualized immunotherapies under one roof – from diagnostics and drug development to manufacturing. Its cutting-edge technologies range from individualized mRNA-based product candidates through innovative chimeric antigen receptors and T-cell receptor-based compounds to novel checkpoint immunomodulators and small molecules. BioNTech’s product development approach has been validated by seven corporate partnerships with, in chronological order, Genmab, Eli Lilly and Company, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Genevant and Pfizer, and its scientific approach through over 60 peer-reviewed scientific publications. Founded in 2008, BioNTech’s financial shareholders include the Struengmann Family Office as its majority shareholder, Fidelity Management & Research Company, Invus, Janus Henderson Investors, MIG Fonds, Redmile Group, Salvia and several European family offices. For more information, please visit: www.biontech.de.
The above testimonials may not be representative of the experience of other customers and is not a guarantee of future performance or success.
This Press Release is for informational purposes only and does not constitute an offer, invitation or recommendation to buy, sell, subscribe for or issue any securities. While the information provided herein is believed to be accurate and reliable, Objective Capital Partners and BA Securities, LLC make no representations or warranties, expressed or implied, as to the accuracy or completeness of such information. All information contained herein is preliminary, limited and subject to completion, correction or amendment. It should not be construed as investment, legal, or tax advice and may not be reproduced or distributed to any person. Securities and investment banking services are offered through BA Securities, LLC Member FINRA, SIPC. The Principal of Objective Capital Partners are registered representative of BA Securities, LLC. Objective Capital Partners and BA Securities, LLC are separate and unaffiliated entities.